ReviewThe Journal of antimicrobial chemotherapy2010
A potential role for daptomycin in enterococcal infections: what is the evidence?
Review in The Journal of antimicrobial chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 93 citations in OpenAlex.
- The DUF998 family protein DrmA modulates cationic glycolipid levels and the emergence of high-level daptomycin resistance inbioRxiv : the preprint server for biology · 2026Article
- Functional Genomics of Antibiotic Susceptibility in Enterococcus faecalis From Infective Endocarditis.The Journal of infectious diseases · 2025Article
- Chemoenzymatic Modification of Daptomycin: Aromatic Group Installation on Trp1.Chembiochem : a European journal of chemical biology · 2024Article
- Article
- Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.Pathogens (Basel, Switzerland) · 2020Review
- Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection.Antibiotics (Basel, Switzerland) · 2019Article
- Article
- Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.Antimicrobial agents and chemotherapy · 2018Article
- A rationale for combination ampicillin and daptomycin in renal transplant patients with enterococcal infective endocarditis.IDCases · 2018Article
- Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors.Epidemiology and infection · 2016Article
- Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- Characterization of daptomycin non-susceptible Enterococcus faecium producing urinary tract infection in a renal transplant recipient.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2015Article
- Multiple roles for Enterococcus faecalis glycosyltransferases in biofilm-associated antibiotic resistance, cell envelope integrity, and conjugative transfer.Antimicrobial agents and chemotherapy · 2015Article
- Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.International journal of antimicrobial agents · 2014Review
- Mechanisms of antibiotic resistance in enterococci.Expert review of anti-infective therapy · 2014Review
- Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.Antimicrobial agents and chemotherapy · 2014Article
- Methicillin-Resistant Staphylococcus aureus Prostatic Abscess in a Liver Transplant Recipient.Case reports in transplantation · 2014Article
- A current perspective on daptomycin for the clinical microbiologist.Clinical microbiology reviews · 2013Review
- Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.International journal of clinical pharmacy · 2013Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal infection models and has been used for the treatment of enterococcal infections in humans. In recent years, large-scale susceptibility studies have shown that daptomycin is active against >98% of enterococci tested, irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reflects the fact that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides. While there are limited data available from randomized controlled trials, extensive clinical experience with daptomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and urinary tract infections) has been reported. This growing body of evidence provides useful insights regarding the efficacy of daptomycin against enterococci in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.